tirzepatide landmark trial for masld Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual and triple agonists The Triad of Risk: Linking

Garcia-Marcos L, Gonzlez-Daz C, Garvajal-Uruea I, PacSa MR, Busquets-Monge RM, Surez-Varela MM, et al

of VA Medical Center, Memphis, University of Tennessee, for his intellectual insights, help in figure drawing, and reading the manuscript

Adding 15 grams of fiber overnight to a sensitive GI system will cause bloating, cramping, and gas

Weight loss in response to chronic semaglutide treatment can be divided into distinct phases, and each phase is characterized by different effects on food intake, meal patterns, energy expenditure, and substrate oxidation

No, nightmares are not listed as a recognised side effect in the MHRA-approved prescribing information for Wegovy, and large-scale clinical trials have not identified sleep disturbances as a significant adverse event